Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31)

被引:62
作者
Lawton, CA
Winter, K
Byhardt, R
Sause, WT
Hanks, GE
Russell, AH
Rotman, M
Porter, A
McGowan, DG
DelRowe, JD
Pilepich, MV
机构
[1] RTOG,STAT UNIT,PHILADELPHIA,PA
[2] LDS HOSP,CTR RADIAT,SALT LAKE CITY,UT
[3] FOX CHASE CANC CTR,DEPT RADIAT ONCOL,PHILADELPHIA,PA 19111
[4] RADIAT ONCOL CTR,SACRAMENTO,CA
[5] SUNY HLTH SCI CTR,DEPT RADIAT ONCOL,BROOKLYN,NY 11203
[6] WAYNE STATE UNIV,DEPT RADIAT ONCOL,DETROIT,MI 48202
[7] UNIV ALBERTA,DEPT RADIAT ONCOL,EDMONTON,AB T6G 2M7,CANADA
[8] ALBERT EINSTEIN COLL MED,BRONX,NY 10467
[9] C MCAULEY HLTH CTR,DEPT RADIAT ONCOL,ANN ARBOR,MI
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1997年 / 38卷 / 05期
关键词
prostate carcinoma; positive lymph nodes; irradiation; antiandrogens;
D O I
10.1016/S0360-3016(97)00288-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the effect of immediate androgen suppression in conjunction with standard external beam irradiation vs, radiation alone on a group of pathologically staged lymph node-positive patients with adenocarcinoma of the prostate, Methods and Materials: A national prospective randomized trial (RTOG 85-31) of standard external beam irradiation plus immediate androgen suppression vs, external beam irradiation alone was initiated in 1985 for patients with locally advanced adenocarcinoma of the prostate, One hundred seventy-three of the patients in this trial had biopsy-proven pathologically involved lymph nodes, Ninety-eight of these patients received radiation plus the immediate androgen suppression (LHRH agonist), while 75 received radiation alone with hormonal manipulation instituted at the time of relapse, Results: With a median followup of 4.9 years, estimated progression-free survival with PSA < 1.5 ng/ml at 5 years was 55% for the patients who received radiation plus immediate LHRH agonist vs, 11% of the patients who received radiation alone with hormonal manipulation at relapse (p = 0.0001), Because all of these patients had locally advanced disease (i.e., pathologically positive lymph nodes), stage does not explain this difference in outcome, and Gleason grade was not statistically different between the two groups, Estimated absolute survival at 5 years for the radiation and LHRH group was 73 vs, 65% for the radiation alone group who received androgen suppression at relapse, Estimated disease-specific survival at 5 years was 82% for the radiation and immediate LHRH agonist group and 77% for the radiation-alone group, Conclusion: Patients with adenocarcinoma of the prostate and pathologically involved pelvic lymph nodes (pN+ or clinical stage D1) should be seriously considered for external beam irradiation plus immediate hormonal manipulation over radiation alone with hormonal manipulation at the time of relapse. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:931 / 939
页数:9
相关论文
共 23 条
[11]  
NESBIT RM, 1946, SURGERY, V20, P263
[12]  
PAULSON D, 1990, EORTC GENITOURINARY, V7, P167
[13]   EXTENDED FIELD RADIATION-THERAPY VERSUS DELAYED HORMONAL-THERAPY IN NODE POSITIVE PROSTATIC ADENOCARCINOMA [J].
PAULSON, DF ;
CLINE, WA ;
KOEFOOT, RB ;
HINSHAW, W ;
STEPHANI, S ;
WULFSOHN, MA .
JOURNAL OF UROLOGY, 1982, 127 (05) :935-937
[14]   Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31 [J].
Pilepich, MV ;
Caplan, R ;
Byhardt, RW ;
Lawton, CA ;
Gallagher, MJ ;
Mesic, JB ;
Hanks, GE ;
Coughlin, CT ;
Porter, A ;
Shipley, WU ;
Grignon, D .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :1013-1021
[15]  
*RTOG RAD THER ONC, RTOG RAD THER ONC GR
[16]  
SCHMIDT JD, 1993, CANCER, V71, P1005, DOI 10.1002/1097-0142(19930201)71:3+<1005::AID-CNCR2820711418>3.0.CO
[17]  
2-I
[18]  
SIDI AA, 1987, EUR UROL, V13, P238
[19]   THE FRENCH JOYCE - LERNOUT,G [J].
WHITLEY, C .
COMPARATIVE LITERATURE, 1994, 46 (02) :213-215
[20]  
ZAGARS GK, 1994, J UROLOGY, V151, P1130